We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma.
- Authors
Gennatas, Spyridon; Stanway, Susana J; Thomas, Robert; Min, Toon; Shah, Riyaz; O'Brien, Mary E R; Popat, Sanjay
- Abstract
Single arm phase 1 and 2 studies on Crizotinib in ALK-positive patients so far have shown rapid and durable responses. Spontaneous pneumothoraces as a result of response to anti-cancer therapy are rare in oncology but have been documented in a number of tumour types including lung cancer. This includes cytotoxic chemotherapy as well as molecular targeted agents such as gefitinib and Bevacizumab. These often require chest drain insertion or surgical intervention with associated morbidity and mortality. They have also been associated with response to treatment. This is the first report we are aware of documenting pneumothorax as response to crizotinib therapy.
- Publication
BMC cancer, 2013, Vol 13, p207
- ISSN
1471-2407
- Publication type
Journal Article
- DOI
10.1186/1471-2407-13-207